1 Division of Cardiology Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea.
J Am Heart Assoc. 2018 Nov 6;7(21):e009517. doi: 10.1161/JAHA.118.009517.
Background Whether use of high-intensity statins is more important than achieving low-density lipoprotein cholesterol ( LDL -C) target remains controversial in patients with coronary artery disease. We sought to investigate the association between statin intensity and long-term clinical outcomes in patients achieving treatment target for LDL -C after percutaneous coronary intervention. Methods and Results Between February 2003 and December 2014, 1746 patients who underwent percutaneous coronary intervention and achieved treatment target for LDL -C (<70 mg/dL or >50% reduction from baseline level) were studied. We classified patients into 2 groups according to an intensity of statin prescribed after index percutaneous coronary intervention: high-intensity statin group (atorvastatin 40 or 80 mg, and rosuvastatin 20 mg, 372 patients) and non-high-intensity statin group (the other statin treatment, 1374 patients). The primary outcome was a composite of cardiac death, myocardial infarction, or stroke. Difference in time-averaged LDL -C during follow-up was significant, but small, between the high-intensity statin group and non-high-intensity statin group (59±13 versus 61±12 mg/dL; P=0.04). At 5 years, patients receiving high-intensity statins had a significantly lower incidence of the primary outcome than those treated with non-high-intensity statins (4.1% versus 9.9%; hazard ratio, 0.42; 95% confidence interval, 0.23-0.79; P<0.01). Results were consistent after propensity-score matching (4.2% versus 11.2%; hazard ratio, 0.36; 95% confidence interval, 0.19-0.69; P<0.01) and across various subgroups. Conclusions Among patients achieving treatment target for LDL -C after percutaneous coronary intervention, high-intensity statins were associated with a lower risk of major adverse cardiovascular events than non-high-intensity statins despite a small difference in achieved LDL -C level.
在经皮冠状动脉介入治疗(PCI)后达到 LDL-C 治疗目标的患者中,高强度他汀类药物的使用是否比达到 LDL-C 目标更重要仍存在争议。我们旨在研究 PCI 后达到 LDL-C 治疗目标的患者中,他汀类药物强度与长期临床结局之间的关系。
2003 年 2 月至 2014 年 12 月,研究了 1746 例接受 PCI 且达到 LDL-C 治疗目标(<70mg/dL 或较基线水平降低>50%)的患者。我们根据 PCI 后处方他汀类药物的强度将患者分为 2 组:高强度他汀类药物组(阿托伐他汀 40 或 80mg 和瑞舒伐他汀 20mg,372 例)和非高强度他汀类药物组(其他他汀类药物治疗,1374 例)。主要结局为心脏性死亡、心肌梗死或卒中的复合终点。高强度他汀类药物组与非高强度他汀类药物组之间的平均 LDL-C 差异在随访期间虽有统计学意义,但很小(59±13mg/dL 比 61±12mg/dL;P=0.04)。5 年时,接受高强度他汀类药物治疗的患者主要结局发生率显著低于接受非高强度他汀类药物治疗的患者(4.1%比 9.9%;风险比,0.42;95%置信区间,0.23-0.79;P<0.01)。在倾向评分匹配后结果一致(4.2%比 11.2%;风险比,0.36;95%置信区间,0.19-0.69;P<0.01),且在各个亚组中结果一致。
在经 PCI 后达到 LDL-C 治疗目标的患者中,与非高强度他汀类药物相比,高强度他汀类药物与主要不良心血管事件风险降低相关,尽管 LDL-C 水平的差异较小。